Key Highlights

  • A failed Phase 2 Alzheimer's trial preceded Acumen Pharmaceuticals' 85.77% decline to $0.33.
  • SmartKem's price sits at $0.304 after a 25.96% fall, under a 52-week low of $0.40.
  • FingerMotion dropped 24.28% to $0.108, while its year-end cash stood at just $68,596.
  • INLIF has lost roughly 92% from its $2.55 close on Oct 16, a figure computed from the reported prices, after a registered direct offering.
  • Averaged over the five, the decline comes to 35.42% (calculated).

Which Stocks Under $1 Are Sliding the Hardest Today?

Five stocks priced below $1 lead the drops in this ranking on Oct 30, 2026, arranged by the size of decline. Acumen Pharmaceuticals (NASDAQ:ABOS) is at $0.33 after falling 85.77%, SmartKem (NASDAQ:SMTK) at $0.304 after 25.96%, FingerMotion (NASDAQ:FNGR) at $0.108 after 24.28%, INLIF (NASDAQ:INLF) at $0.2099 after 20.79%, and NetClass Technology (NASDAQ:NTCL) at $0.4305 after 20.29%.

Percentages are measured from each stock's previous close, so the bases vary. Several of these companies have passed through reverse stock splits, which distorts comparisons with older prices. The ranking describes price movement alone and takes no stance on any company's direction.

Only Acumen points to a clear announcement made today, a failed clinical trial. SmartKem, FingerMotion, INLIF and NetClass have no company announcement dated today, so the background offered below draws on recent filings rather than an established cause. Several supporting numbers, including older market values and 52-week ranges, are approximations drawn from earlier data snapshots.

1. Acumen Pharmaceuticals: a failed Alzheimer's study behind the 85.77% collapse

Phase 2 ALTITUDE-AD, a study of sabirnetug in early Alzheimer's disease that enrolled 542 participants, came back without a win on its primary endpoint at either tested dose, and key secondary endpoints fell short as well. Amyloid plaque declined at both doses, but cognition and function showed no measurable improvement.

Sabirnetug development is set to stop, and Acumen plans a review of strategic alternatives, among them the Enhanced Brain Delivery program. Cash and marketable securities stood at $110.2 million on June 30, 2026, which the company said would carry operations into early 2027. The current share price implies a Market Value near $24 million on roughly 72.3 million shares, a rough estimate. Research and Development expense fell to $27.8 million in the second quarter, and no further reduction target has been disclosed.

2. SmartKem: the filings behind a slide to $0.304

SmartKem has dropped 25.96% to $0.304, from a prior close near $0.41, and no company announcement dated today was found. The stock trades below its 52-week low of $0.40 and far beneath the $2.35 last-sale price noted in a Sept 16 filing.

This company manufactures custom electronic materials, including its TRUFLEX line. Filings describe an August 1-for-50 reverse split, an Equity purchase agreement permitting share sales of up to $500 million, and a Merger still pending with Ferrox Critical Minerals, valued near $125 million, to be paid in stock. Going-concern language appeared in the auditors' reports for 2025 and 2024.

3. FingerMotion: a 24.28% decline to $0.108 alongside shrinking Revenue and cash

FingerMotion is off 24.28% at $0.108, down from a prior close near $0.143, with no same-day announcement identified. Revenue for the year ended Feb 28, 2026 fell 32% to $24.13 million, and the net loss grew 37% to $7.0 million, despite a 12% cut in operating expenses to $7.63 million.

The Singapore-based company supplies mobile payment and recharge services, Data Analytics and digital applications, largely in China. Year-end cash was only $68,596, and the $5 million convertible note issued May 13, 2026 has a $0.94 fixed conversion price, well above the current level. A data page put the 52-week range at $0.13 to $1.74 as of Oct 19, meaning the stock now trades beneath that low.

4. INLIF: linking the 20.79% slide to the October registered direct offering

INLIF is at $0.2099, down 20.79%. No new company announcement was identified today. The slide tracks a registered direct offering disclosed Oct 19, after which the stock dropped roughly 84%, from a $2.55 close to about $0.41. That offering priced shares at $1.60, bundled with Series A, B and C warrants, and brought in around $3.75 million.

Series A and B warrants carry a one-time downward adjustment to their exercise prices, while the Series C formula can issue additional shares if the price remains depressed. The company manufactures manipulator arms for injection molding machines through its operating Business in China. First-half 2026 revenue rose 26.01% to $12.94 million, with Net Income of $1.01 million, yet the $45.47 million cash balance appears inconsistent with the modest raise and has not been verified.

5. NetClass Technology: a 20.29% decline through its 52-week low with no fresh news

NetClass is trading at $0.4305, down 20.29% and under the 52-week low of $0.6316 shown in market data as of Oct 27. The research identified no company-specific announcement. The most recent corporate item was the Oct 9 debut of the LinkeeBot AI pet, launched through a joint venture where NetClass owns 40%.

This Singapore and Hong Kong-based company provides business-to-business education software. Fiscal 2025 revenue came to $9.81 million, down 2.94%, with a net loss of $10.82 million. Market data from Oct 27 indicated a Capitalization near $1.79 million following a 1-for-50 share consolidation, and no cash figure appeared in the sources reviewed.

Sub-$1 Decliners Compared: Mean Decline, Range of Drops and Price Ratios

Averaged together, the five declines come to 35.42% (calculated). Leaving Acumen out, the remaining four average 22.83% (calculated) and cluster within a tight band of 20.29% to 25.96%.

Top to bottom, the drops are separated by 65.48 percentage points (calculated). Acumen's fall is about 3.30 times the size of SmartKem's, the next-largest decline (calculated). On price, NetClass at $0.4305 sits roughly 3.99 times FingerMotion's $0.108 (calculated). Bases differ because some stocks trade on post-reverse-split prices, and only Acumen's drop has a clear same-day announcement.

What to Watch Next: Acumen Readouts, the Ferrox Deal Clock and INLIF's Warrant Resets

Acumen has flagged more fluid biomarker and imaging data for the weeks ahead, together with cash conservation specifics. The SmartKem merger agreement permits either party to walk away if the Ferrox transaction is not completed by Mar 31, 2027, and Shareholder approval plus an effective Form S-4 are still outstanding.

FingerMotion's convertible note reaches Maturity one year after its May 2026 closing, and a stockholder vote on additional conversion shares could become important. INLIF's warrants adjust on the twentieth trading day following the Oct 20, 2026 closing, though the sources Supply no calendar date. No Earnings date has been confirmed for NetClass, leaving no dated release on record for the company.